Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: An immunohistochemical study of metastatic ovarian serous carcinoma

Cancer Cytopathology

Volumn 118, Issue 5, 2010, Pages 298-302

  McKnight, Ryan ^a   Cohen, Cynthia ^a   Siddiqui, Momin T ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Calretinin; Immunohistochemistry; Ovarian serous carcinoma; Paired box gene 8 (PAX8); Pelvic fluid; Peritoneal fluid; WT1

Indexed keywords

CALBINDIN; CALRETININ; HUMAN EPITHELIAL ANTIGEN 125; HUMAN EPITHELIAL ANTIGEN-125; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN; TUMOR MARKER; WT1 PROTEIN;

ARTICLE; BIOSYNTHESIS; BODY FLUID; CYSTADENOCARCINOMA; CYTODIAGNOSIS; CYTOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; METHODOLOGY; NEEDLE BIOPSY; OVARY TUMOR; SENSITIVITY AND SPECIFICITY;

BIOPSY, FINE-NEEDLE; BODY FLUIDS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CYSTADENOCARCINOMA, SEROUS; CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 79952114665     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20089     Document Type: Article

References (13)

1. Tavassoli, T, Deville, P. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
3. Lee BH, Hecht JL, Pinkus JL, Pinkus GS. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
4. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
5. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology. 2002;40:237-244.
6. Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol. 2001;116:709-715.
7. Okamoto S, Ito K, Sasano H, et al. Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med. 2005;206:31-40.
8. Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol. 2004;12:122-126.
9. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804-814.
10. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2010.
11. Poleev A, Fickenscher H, Mundlos S, et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development. 1992;116:611-623.
12. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337.
13. Morgan RL, De Young BR, McGaughy VR, Niemann TH. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer (Cancer Cytopathol). 1999;87:390-394.